

The Identification and Prevention of Necrotizing Enterocolitis


Josef Neu, M.D.
neuj@peds.ufl.edu
University of Florida

NEO THE CONFERENCE
FOR NEONATOLOGY

Disclosure

Dr. Neu has disclosed the following financial relationships. Any real or apparent conflicts of interest related to the content of this presentation have been resolved.

Affiliation / Financial Interest	Organization
Global Scientific Council	Nestle Nutrition Institute
Scientific Advisory Board	Astarte
Scientific Advisory Board	Medela
Research Grant	Infant Bacterial Therapeutics
Speakers Bureau	Mead Johnson
Expert Witness	Abbott Laboratories
Expert Witness	Winston & Strawn LLP

A photograph of a dirt road winding through a forest. The road is covered in fallen leaves and grass. The trees are mostly bare, suggesting autumn or winter. The sky is overcast. The text is overlaid on the center of the image.

Then I feel so happy and
at the same time so sad,
it's unimaginable.

Anton Chekhov


NIH report recommends strategies for advancing research on necrotizing enterocolitis

Thursday, September 19, 2024




Quiz

1. Please define neonatal necrotizing enterocolitis.
2. Is necrotizing enterocolitis a distinct disease?
3. Do babies with Bell's Stage 1 or 2 "NEC" have intestinal necrosis?
4. Do we have a clear understanding of the pathophysiology of "NEC"?
5. Do we have accurate biomarkers for NEC?
6. Are there clearly effective preventative strategies?
7. Should we start over again and redefine intestinal injuries and feeding dysfunctions we are calling "NEC"?



1965



1971

Historical Perspective: Being led astray: 60 years--not much progress



- Lumping of several diseases called “NEC” into the same data set.
- Animal models do not correctly represent what we see in human preterms.
- Narrow focus on individual pathways rather than systems.



“NEC”



Defining Necrotizing Enterocolitis: Current Difficulties and Future Opportunities

Ravi Mangal Patel, MD, MSc¹, Joanne Ferguson, BSc², Steven J. McElroy, MD³, Minesh Khashu, MBBS, FRCPCH, MD^{4,5}, Michael S. Caplan, MD⁶


¹Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA. ²Special Interest Group in Necrotizing Enterocolitis (SIGNEC), Belfast, Northern Ireland. ³Stead Family Department of Pediatrics, Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA ⁴Poole Hospital NHS Foundation Trust, Poole, Dorset, U.K. ⁵SIGNEC, Poole, Dorset, U.K. ⁶Department of Pediatrics, NorthShore University Health System, Evanston, IL, USA

Abstract

Necrotizing enterocolitis (NEC) is a leading cause of morbidity and mortality in hospitalized infants. First classified through Bell staging in 1978, a number of additional definitions of NEC have been proposed in the subsequent decades. In this review, we summarize 8 current definitions of NEC, and explore similarities and differences in clinical signs and radiographic features included within these definitions, as well as their limitations. We highlight the importance of a global consensus on defining NEC to improve NEC research and outcomes, incorporating input from participants at an international NEC conference. We also highlight the important role of patient-families in helping to redefine NEC.

Defining a disease or condition has important implications. Meeting a set of criteria for a

What do we call “NEC”



NEC Pathophysiology



Warning: We are talking about current concepts of pathophysiology, diagnosis and treatment. If we don't have a good definition and if what we are calling "NEC" is several different entities, then how can we trust our current data sets, basic and clinical studies?

Disclaimer: The following part of this presentation about pathophysiology will discuss our current understanding and will hopefully be refined soon.

Rat model of "NEC".





Preterm vs. Term Intestine




Healy, DB. Et al, Nature Microbiology, 2022

“Classic” NEC



Pathophysiologic Overview at the Barrier: A Perfect Storm




Mean Corrected Gestational Age at NEC Diagnosis



23 week preterm




29 week preterm







Pammi, M. et al. Microbiome, 2017

Major Microbiome Sequencing Technologies



Adapted from : <https://www.neb.com/tools-and-resources/feature-articles/addressing-challenges-in-microbiome-dna-analysis>





Contents lists available at ScienceDirect

Seminars in Fetal and Neonatal Medicine

journal homepage: www.elsevier.com/locate/siny



Necrotizing enterocolitis comes in different forms: Historical perspectives and defining the disease



J. Neu^{a,*}, N. Modi^b, M. Caplan^c

^a University of Florida, College of Medicine, Gainesville, FL, USA

^b Imperial College London, London, UK

^c University of Chicago Pritzker School of Medicine, NorthShore University Health System, Evanston, IL, USA

ARTICLE INFO

Keywords:

Necrotizing enterocolitis

Pathophysiology

Differential diagnosis

ABSTRACT


The specific cause of what is commonly referred to as necrotizing enterocolitis (NEC) disease has been elusive largely because it is becoming clear that this entity represents more than one disease with multifactorial pathogenic mechanisms. Furthermore, finding clear and consistent diagnostic biomarkers will be difficult until the different subsets of what we are calling this disease are better delineated. In this introductory chapter, we discuss different disease entities that are frequently termed “NEC” in the newborn infant. We hope this will set the stage for more focused research and development of preventative measures for at least the most common forms of this disease.

Diagnostic Challenges: Status of Data Bases




29-week Gestation Preterm: Abdomen Soft, baby taking NG feeds well but Incidental Finding on Radiograph

“Poopatosiis”



**25 week Preterm, 5 days old,
breast milk, on hydrocortisone for
“hypotension”---distended
abdomen.**





Is there a Clear Definition of NEC? Bells is Broken



- Stage 1-Too non-specific and the term should not be used.
- Stage 2-Radiographic signs can be “fuzzy”.
- Stage 3- Free air on radiograph could signify intestinal necrosis or Spontaneous Intestinal Perforation (SIP)

When studies find an

ASSOCIATION

between two things



it does **not** mean one thing

CAUSED

the other one to happen.

VIEWPOINT

When Biological Causality Is Determined in a Court of Law

Josef Neu, MD; Neena Modi, MD

There are currently thousands of lawsuits being litigated in the US against physicians, nurses, hospitals, and industry related to 2 recent court rulings that formula causes necrotizing enterocolitis (NEC) in preterm infants. These are symptomatic of a much larger issue that involves courts conflating association with causation, other examples of which are lawsuits relating to claims that agents such as talc cause certain cancers and acetaminophen taken during pregnancy causes autism in offspring. The legal process also places enormous value on the views of individuals, although medicine has long eschewed this in favor of systematic reviews of peer-reviewed evidence and statistical analyses that incorporate formal measures of probability. A current cause célèbre is the growing tide of criticism against legal acceptance of “expert” opinion, and flawed interpretation of data, that was instrumental in the conviction of a neonatal nurse, Lucy Letby, for the murder of 7 infants.¹ Targets for litigation are easy to find as associations abound. NEC litigation has been encouraged through advertising by solicitors to distraught parents, persuading them that a specific action, the feeding of formula, was the cause of their infant’s intestinal problems. Medicine and the law preside over life-changing decisions: surely an understanding of scientific method for determining causality, and ethical standards of behavior, should be an essential requirement for both?

In this Viewpoint, we discuss the (1) lack of a clear definition and

human donor milk is also protective. However, a whole-population 2-year surveillance study in England and Wales showed that 50% of infants developing NEC resulting in surgery and/or death had received only human milk feeds before onset.³

Clinical trial evidence to date is inconclusive. A Cochrane Library systematic review identified 9 small randomized clinical trials (RCTs) that compared donor milk and formula as either sole diet or supplement to an infant’s own mother’s milk and included NEC as an outcome.⁴ Meta-analysis in which the comparison combined trials of sole and supplementary diets shows higher risk with formula (relative risk, 1.87; 95% CI, 1.23-2.85). However, the Cochrane reviewers sound several notes of caution. The majority of the RCTs took place in the 1970s and 1980s, when the patient population differed substantially from that of today; sample sizes were inadequate, methodological quality was poor, and no differences were shown in key outcomes such as mortality and sepsis that would be important corroboration of benefit.

Patient Safety Considerations

Infants are harmed when their own mother’s milk is unavailable. Mothers of very preterm infants who want to breastfeed must express milk for many weeks because the developmental maturity to suckle is only reached at around 32 to 34 weeks’ gestation. This

**The term “NEC” has been
misused for decades!!**

**Why should we say “necrosis”
when the evidence in most
cases is lacking?**

Preventative Strategies



Routine Use of Probiotics for Prevention of “NEC”



Meta-Analysis -NEC

Review: Probiotics for prevention of necrotizing enterocolitis
 Comparison: 01 NEC
 Outcome: 01 Definite NEC




FIGURE 2
 Effect of probiotics on NEC.

Deshpande, G. Pediatrics, 2010

Cochrane Review of 60 trials with 11,156 infants: July 26, 2023

Authors' conclusions:

Given the low to moderate certainty of evidence for the effects of probiotic supplements on the risk of NEC and associated morbidity and mortality for very preterm or VLBW infants, and particularly for extremely preterm or ELBW infants, there is a need for further large, high-quality trials to provide evidence of sufficient validity and applicability to inform policy and practice.



Use of Probiotics in Preterm Infants

Brenda Poindexter, MD, MS, FAAP, COMMITTEE ON FETUS AND NEWBORN

Probiotic products in the United States are available for use in the general category of dietary supplements, bypassing the rigor of the US Food and Drug Administration (FDA) approval process in safety, efficacy, and manufacturing standards. As a result, currently available probiotics lack FDA-approved drug labeling and cannot be marketed to treat or prevent disease in preterm infants, including necrotizing enterocolitis and late-onset sepsis. Despite lack of availability of a pharmaceutical-grade product, the number of preterm infants receiving probiotics in the United States and Canada is steadily increasing. According to recent reports from large collaborative databases in the United States, approximately 10% of extremely low gestational age neonates receive a probiotic preparation during their stay in the NICU, with wide variation in practice among units. In sum, more than 10 000 preterm infants have been enrolled in randomized clinical trials of probiotic supplementation worldwide. Methodologic differences among study protocols included different strains and combinations of therapy; masking of trials, and a priori definitions of the primary outcome measure. Large meta-analyses of these trials have demonstrated the efficacy of multiple-strain probiotics in reducing necrotizing enterocolitis and all-cause mortality, whereas the efficacy of single-strain probiotic preparations is less certain. In the absence of an appropriate medical-grade product in the United States, dietary supplement-grade probiotics, some of which have been the subject of recent recalls for contamination, are being prescribed. Given the lack of FDA-regulated pharmaceutical-grade products in the United States, conflicting data on safety and efficacy, and potential for harm in a highly vulnerable population, current evidence does not support the routine, universal administration of probiotics to preterm infants, particularly those with a birth weight of <1000 g.

abstract

Children's Healthcare of Atlanta and School of Medicine, Emory University, Atlanta, Georgia

Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of hospitals and academic medical centers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the hospitals or the organizations or government agencies that they represent.

Dr Poindexter was responsible for conceptualizing, writing, and revising the manuscript and considering input from all reviewers and the board of directors; the author approved the final manuscript as submitted.

The guidance in this clinical report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither selected nor accepted any commercial involvement in the development of the content of this publication.

DOI: <https://doi.org/10.1542/peds.2021-081805>

Address correspondence to Brenda Poindexter, MD. E-mail: brenda.poindexter@emory.edu

PEDIATRICS (ISSN Numbers: Print, 0007-1226; Online, 1098-4275).

“Given the lack of FDA-regulated pharmaceutical Grade products in the United States, conflicting data on safety and efficacy,, and potential for harm in a highly vulnerable population, current evidence does not support the routine universal administration of probiotics to preterm infants, particularly with a birthweight of <1000 grams.”

**What is the
difference between
a probiotic and a Live
Biotherapeutic
Product?**

Connection Study: Historical Perspective

2012 - Work initiated by IBT (Infant Bacterial Therapeutics). Existing data was unclear with several small trials, meta-analyses.

2013 - Discussions commenced with FDA and European Agency.


2016 - Initiation of Phase 2 trial under IND.

2016- ongoing - Safety concerns about probiotic agents (mucormycosis, sepsis, most recent FDA warning after sepsis and death).

2024 - Enrollment of Phase 3 Connection study completed in summer.

Objectives

Evaluate the first live biotherapeutic product, IBP-9414 vs. sterile water placebo in very low birthweight infants in terms of:

- Safety
 - Prevention of NEC (primary endpoint)
 - Improved sustained feeding tolerance (primary endpoint)
 - Reduction of deaths due to any causes (secondary endpoint)
 - Decrease in severity of NEC
 - Other prespecified outcomes such as length of hospitalization, growth, other morbidities
- 
- A large yellow triangle is positioned in the bottom right corner of the slide, pointing towards the top right.

2117 Treated Infants

Birth weight 500-1,500 grams (overall median 850 grams)

- 551 infants (26%) with 500-749 grams
- 1351 infants (64%) with 750-1,000 grams
- 215 infants (10%) with 1,001-1,500 grams

Females (50%), Caucasian (58%), Black/African American (27%), cesarean section (77%)

Well balanced groups treated with IBP-9414 and placebo with respect to birth weight, age, sex, geographic region, race, ethnicity, method of delivery etc

Necrotizing Enterocolitis (NEC)

NEC	IBP-9414	Placebo	RR (95% CI)	P
NEC, all mITT	93 (8.7%)	107 (10.2%)	0.86 (0.66 - 1.11)	0.248

1. (mITT) population (defined as infants receiving at least one dose of IBP-9414)

Necrotizing Enterocolitis (NEC)

NEC	IBP-9414	Placebo	RR (95% CI)	P
NEC, all mITT	93 (8.7%)	107 (10.2%)	0.86 (0.66 - 1.11)	0.248
NEC beyond day 14d	59 (5.7%)	79 (7.7%)	0.74 (0.53-1.02)	0.067


Taking the heterogeneity of the disease, the difficulty in x-ray analysis and time required for the pharmacodynamic effect

NEC by surgery beyond day 14d	3 (0.3%)	10 (1.0%)	0.29 (0.08-1.06)	0.046
-------------------------------	----------	-----------	------------------	-------

1. (mITT) population (defined as infants receiving at least one dose of IBP-9414)

IBP-9414 - Reduction of Mortality

All-cause deaths	IBP-9414	Placebo	RR (95% CI)	p
Deaths mITT	66 (6.2%)	89 (8.5%)	0.73 (0.54 - 0.98)	0.036
Deaths, beyond 14d	22 (2.2%)	40 (4.0%)	0.54 (0.33-0.89)	0.014



- Pharmacodynamic effect of IBP-9414 observed after 14 days of treatment
- Preventive effects on mortality coincides with when NEC and BPD occur in preterm infants

1. (mITT) population (defined as infants receiving at least one dose of IBP-9414)

Conclusions

Largest study ever of a live biotherapeutic product in premature infants

- Numerical benefit of IBP-9414 treatment on NEC and SFT
 - NEC ambiguous clinical diagnosis unless laparotomy or autopsy are performed
 - SFT hampered by variable adherence to advocated enteral feeding protocol
- Significant reduction of the risk of death from any cause
- No concerns as to safety
- *Lactobacillus reuteri* never found in blood cultures taken for clinical suspicion of sepsis


Positive benefit-risk of IBP-9414 in premature infants born at very low birth weight

Canadian Study: “Effectiveness and Risks of Probiotics in Preterm Infants” :

Alshaikh BN, Ting J, Lee S, et al. Effectiveness and Risks of Probiotics in Preterm Infants. Pediatrics. 2025;155 (3):e2024069102

- Review of 32,667 infants born before 34 weeks gestation in Canadian Neonatal Network. Probiotics vs. no probiotics.
- No difference in NEC or sepsis between the groups.
- Decreased mortality rate (aOR 0.62, CI 0.53-0.73).
- Probiotic sepsis seen in 31 infants, 3 died.

Studies on “NEC” are problematic: WHY?



COMMENT



INVITED COMMENTARY

Definitions of necrotizing enterocolitis: What are we defining and is machine learning the answer?

Camilia R. Martin^{1,2}✉

© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2021

Pediatric Research (2022) 91:488–489; <https://doi.org/10.1038/s41390-021-01687-0>

The quest to adequately define, diagnose, and manage human disease is recorded as early as 2600 BC as evidenced by the Egyptian Edwin Smith Papyrus.¹ This process continues to be iteratively explored and updated as new approaches (e.g., the scientific method and evidence-based medicine) and new information become available with advancing technologies. Disease classifications can serve many purposes. It can be used to diagnose, predict disease risk, optimize therapeutics, assess morbidity and/or mortality, determine quality of life and health care utilization, and predict long-term medical needs. At the same time, ideally, disease classification should not overdiagnose or overtreat. All these elements are important when considering necrotizing enterocolitis (NEC), the infants it afflicts, and the families it impacts.

It is often discussed that Dr. Martin Bell proposed the first “definition” of NEC in 1978.² However, this is not a definition of the


get NEC? What is a reliable set of risk factors that are modifiable and are subject to practice change and early therapies to minimize the risk of disease? To resolve these issues, it rests on us to determine a robust definition of disease presence and here we enter a continuous imperfect circular argument.

Six definitions have since been proposed in the literature to chip away at our clinical uncertainties and were recently analyzed in a thorough review by Patel et al.⁸ The more contemporary definitions include the Vermont Oxford Network definition, the Centers for Disease Control and Prevention definition, the gestational age-specific case definition of NEC (UK), the two out of three rule, the Stanford NEC score, and the International Neonatal Consortium NEC workgroup definition. With now a handful of models to potentially use for clinical and research purposes, should the dominant position of the modified Bell’s criteria be replaced?


The Future:

How can we mesh AI with multiomics and diagnostics and therapeutics in neonatology?

Unsupervised Machine Learning



Unsupervised machine learning: Starting all over again



COMMENT



Artificial intelligence to classify acquired intestinal injury in preterm neonates—a new perspective

Alain Cuna^{1,2,4}, Muralidhar H. Premkumar^{2,4} and Venkatesh Sampath^{1,2} 



© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2024

Pediatric Research <https://doi.org/10.1038/s41390-024-03148-w>


In conclusion, this study represents a promising and novel approach to redefining acquired neonatal intestinal diseases, including NEC and SIP, using unsupervised machine learning. This predominantly phenomics' approach can be substantially improved upon in future studies by incorporating large datasets from multiple centers and by including more learning features combining clinical, laboratory, radiographic, genomic, metabolomic, and microbiota data.^{1–4} In the quest for better classification of acquired neonatal intestinal diseases, the intent to develop tools that can be applied in the clinical and research setting should be paramount. Ideally, such endeavors would redefine disease according to pathophysiologic mechanisms, which in turn could provide new paths to prevention and therapy. Any new reclassification schemes based on machine learning should undergo prospective evaluation to ascertain their performance and real-world impact in the clinical setting.



Developing an Improved Taxonomy: Why Multiomics



Multiomic Integration



Systems Biology Mechanism

Strategy for the Future (one possible approach)

1. Make believe the term necrotizing enterocolitis never existed for neonates.
2. Evaluate large datasets of preterm infants with various forms of feeding intolerance, putative intestinal problems, defined intestinal problems and perform unsupervised clustering.
3. Prospectively cluster infants using unsupervised AI, collect samples and utilize integrated multiomics to interrogate mechanisms.
4. Delineate clinical features and biomarkers that can be used for early detection for each cluster.
5. Develop preventative and therapeutic measures based on pathophysiologic mechanism.

